Floatz logo

Prevnar

Tinea

Centro Studi GisedN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Tinea cohort.

Asset / SponsorPhaseRating
Activated T Cells
Centro Studi Gised
N/AD
gi-4000
Centro Studi Gised
N/AD

Same molecule, other indications

Prevnar is also rated in:

plasma cell myelomaDormant
B
Indicative ·
56 / 100
View asset →
Multiple MyelomaDormant
CCC
Indicative ·
48 / 100
View asset →
primary peritoneal carcinomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →